NNNN

Company Overview — What Does Anbio Biotechnology Do?

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs. Our comprehensive range encompasses solutions for various applications, including over-the-counter (OTC) utilization, point-of-care (POCT) settings, and laboratory applications. By offering a versatile range of products, we ensure that healthcare providers and patients alike can access reliable and efficient diagnostic tools regardless of the healthcare setting. Our IVD products are designed to detect a wide range of biomarkers associated with critical medical domains. These domains encompass infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. By providing advanced diagnostic capabilities in these areas, we empower healthcare professionals to identify and monitor various conditions, facilitating timely intervention and patient care. Moreover, our IVD products are compatible with multiple sample collection matrices, including serum, plasma, whole blood, feces, urine, and saliva, for both healthcare providers and patients. This flexibility allows for diagnostic testing across diverse patient populations and healthcare settings. Furthermore, the IVD assays we develop utilize established and widely used IVD technology platforms and their scientific principles to allow quick adoption by the healthcare providers and cost-efficient improvements to the already available products on the market. Anbio Biotechnology offers a comprehensive range of IVD products to meet the growing demand in the POCT and OTC market. Our main sales revenue was from SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B Antigen Rapid Test Kit, under our Lateral Flow Immunoassay (LFIA) technology, which accounted for over 60% and 99% of total revenue for the fiscal year ended December 31, 2023 and 2022, respectively, and 44% and 99% of total revenue for the six months ended June 30, 2024 and 2023, respectively. For the six months ended June 30, 2024 and 2023, we generated revenue of $5.85 million and $3.06 million, respectively, of which 44% and 99% were from respiratory diseases and COVID-19 related products. Our non-COVID-19 related IVD products are primarily focused on laboratory and point of care type of solutions. For the six months ended June 30, 2024 and 2023, 63% and 99% of our revenue were generated in the European Union and we have significant customer concentration. For the fiscal years ended December 31, 2023 and 2022, we generated revenue of $6.71 million and $23.54 million, respectively, of which 60% and 99% were from respiratory diseases and COVID-19 related products. Our non-COVID-19 IVD products are primarily focused on laboratory and point of care type of solutions. For the fiscal years ended December 31, 2023 and 2022, 69% and 86% of our revenue were generated in the European Union and we have significant customer concentration. Currently, all of our IVD products are ready for commercialization and do not require additional development. Prior to the sale of our IVD products in the European Union, we must register with the relevant authority for the regulatory approvals in the European Union. We also work with local distributors to determine the regulatory obligations and appropriate strategies for market entry. Currently, our local distribution partners in strategically selected countries cover countries in the EU, APAC, North and South Americas (collectively “Americas”), and Africa listed below: European Union (EU): Germany, France, Italy, Austria, Portugal, Netherlands, Poland, Slovakia, Czech Republic, Croatia, Belgium, Romania, Bulgaria, Greece, Lithuania, and Cyprus. Asia Pacific (APAC): Indonesia, India, Philippines, Malaysia, Thailand, Bangladesh, Pakistan, Hong Kong SAR, United Arab Emirates, and Vietnam Americas: Brazil, Chile, Peru, Bolivia, Guatemala, Colombia, Costa Rica, Paraguay, and Dominican Republic Africa: Nigeria, Ethiopia, Kenya, Uganda, Tanzania, Ghana, Burkina Faso, Cameroon, and Egypt Currently, all of the IVD products are CE marked under the In Vitro Diagnostic Directive (IVDD) 98/79/EC and can be commercialized in the EU. Additionally, we are currently preparing the documentation for the IVDR registration of our IVD products, and we anticipate IVDR approval by the following dates for different device classes: • high individual risk and high public health risk products (Class D): 31 December 2027; • high individual risk and/or moderate public health risk products (Class C): 31 December 2028; • moderate individual risk and/or low public health risk (Class B): 31 December 2029; • low individual risk and low public health risk products placed on the market in a sterile condition (Class A sterile): 31 December 2029. While we do not foresee any setbacks or shortcomings in obtaining regulatory approvals, we cannot guarantee the success of all our registration endeavors. Failure to secure registration for our IVD products in these countries could adversely impact our revenue performance. Since 2023, we have commenced sales of our non-COVID products in countries within the European Union (EU), Americas, APAC, and Africa. Since the IVDR provides a transitional provision, the IVDR approval process would not currently impact the sales of our non-COVID products. To ensure compliance with the evolving IVDR requirements set by regulatory authorities, we must stay vigilant to prevent potential issues that could impact our business in EU. Our principal executive offices are located at Wilhelm Gutbrod Str 21B, 60437, Frankfurt am Main, Germany. Our registered office in the Cayman Islands is located at the offices of Vistra (Cayman) Limited, P. O. Box 31119, Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1 — 1205 Cayman Islands. Our agent for service of process in the United States is C T Corporation System, 128 Liberty Street, New York, NY. Anbio Biotechnology (NNNN) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Michael Lau and employs approximately 27 people. With a market capitalization of $1.1B, NNNN is one of the notable companies in the Healthcare sector.

Anbio Biotechnology (NNNN) Stock Rating — Hold (April 2026)

As of April 2026, Anbio Biotechnology receives a Hold rating with a composite score of 48.5/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.NNNN ranks #993 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Anbio Biotechnology ranks #70 of 838 stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

NNNN Stock Price and 52-Week Range

Anbio Biotechnology (NNNN) currently trades at $26.16. The stock lost $0.69 (2.6%) in the most recent trading session. The 52-week high for NNNN is $55.65, which means the stock is currently trading -53.0% from its annual peak. The 52-week low is $5.89, putting the stock 344.1% above its annual trough. Recent trading volume was 1K shares, suggesting relatively thin trading activity.

Is NNNN Overvalued or Undervalued? — Valuation Analysis

Anbio Biotechnology (NNNN) carries a value factor score of 47/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 479.46x, compared to the Healthcare sector average of 23.63x — a premium of 1929%. The price-to-book ratio stands at 69.88x, versus the sector average of 2.75x. The price-to-sales ratio is 36.69x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, NNNN trades at 146.11x EV/EBITDA, versus 6.34x for the sector.

Overall, NNNN's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

Anbio Biotechnology Profitability — ROE, Margins, and Quality Score

Anbio Biotechnology (NNNN) earns a quality factor score of 41/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 55.2%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 50.2% versus the sector average of -33.1%.

On a margin basis, Anbio Biotechnology reports gross margins of 71.9%, compared to 71.5% for the sector. The operating margin is 24.4% (sector: -66.1%). Net profit margin stands at 29.0%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

NNNN Debt, Balance Sheet, and Financial Health

Anbio Biotechnology has a debt-to-equity ratio of 0.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. Total debt on the balance sheet is $0. Cash and equivalents stand at $12M.

NNNN has a beta of 0.20, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Anbio Biotechnology is 35/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Anbio Biotechnology Revenue and Earnings History — Quarterly Trend

In TTM 2026, Anbio Biotechnology reported revenue of $8M and earnings per share (EPS) of $0.06. Net income for the quarter was $2M. Gross margin was 71.9%. Operating income came in at $2M.

In FY 2024, Anbio Biotechnology reported revenue of $8M and earnings per share (EPS) of $0.06. Net income for the quarter was $2M. Gross margin was 71.9%. Revenue grew 21.9% year-over-year compared to FY 2023. Operating income came in at $2M.

In FY 2023, Anbio Biotechnology reported revenue of $7M and earnings per share (EPS) of $0.10. Net income for the quarter was $2M. Gross margin was 50.1%. Operating income came in at $2M.

NNNN Dividend Yield and Income Analysis

Anbio Biotechnology (NNNN) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

NNNN Momentum and Technical Analysis Profile

Anbio Biotechnology (NNNN) has a momentum factor score of 65/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 45/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 48/100 reflects moderate short selling activity.

NNNN vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Anbio Biotechnology (NNNN) ranks #70 out of 838 stocks based on the Blank Capital composite score. This places NNNN in the top decile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing NNNN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full NNNN vs S&P 500 (SPY) comparison to assess how Anbio Biotechnology stacks up against the broader market across all factor dimensions.

NNNN Next Earnings Date

No upcoming earnings date has been announced for Anbio Biotechnology (NNNN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy NNNN? — Investment Thesis Summary

Anbio Biotechnology presents a balanced picture with arguments on both sides. Price momentum is positive at 65/100, suggesting the trend favors buyers. High volatility (stability score 35/100) increases portfolio risk.

In summary, Anbio Biotechnology (NNNN) earns a Hold rating with a composite score of 48.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on NNNN stock.

Related Resources for NNNN Investors

Explore more research and tools: NNNN vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare NNNN head-to-head with peers: NNNN vs AZN, NNNN vs SLGL, NNNN vs VMD.